Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 71, Issue 4, Pages 443-453Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.11.048
Keywords
cardiovascular; clinical trial; enrollment; Food and Drug Administration; heart failure; recruitment
Categories
Funding
- ResMed
- Merck
- Bristol-Myers Squibb
- Novartis
- AstraZeneca
- CSL Behring
- GlaxoSmithKline
- Janssen
- Portola
- The Medicines Company
Ask authors/readers for more resources
The current heart failure clinical trial environment is strained by increasing complexity and cost, regulatory requirements, competing demands on stakeholders, implementation challenges, and decreasing patient and investigator participation. To begin the process of developing potentially effective strategies and tactics, stakeholders including patients; investigators; academic leaders; pharmaceutical and device industry representatives; society representatives; third-party payers; and government representatives from the U.S. Food and Drug Administration, National Institutes of Health, and Centers for Medicare and Medicaid Services convened in March of 2017. This paper summarizes the discussions, outlines current challenges and actionable opportunities, and makes targeted recommendations to achieve the goals of improving efficiency in clinical trials and speeding the development of effective heart failure therapies, including the formation of an organized Heart Failure Collaboratory. (c) 2018 Published by Elsevier on behalf of the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available